To assess the implications of the drug therapy on mice with scopolamine-induced amnesia, we analyzed the expression of some parameters using immunohistochemistry at the brain level, such as the muscarinic acetylcholine receptor M1 (M1mAChR), the vascular endothelial growth factor A (VEGF-A), cyclooxygenase-2 (COX2), the mammalian target of rapamycin (mTOR), the glial fibrillary acidic protein (GFAP), the major histocompatibility complex class II (MHC II), the cluster of differentiation 68 (CD68), the nuclear factor erythroid 2-related factor 2 (Nrf2) and p65. The gene discussed is CHRM1; the disease is amnesia.